Granules FDA Wednesday, January 29, 2025 +0.80 Positive

FDA Approves LISDEXAMFETAMINE DIMESYLATE — Granules Pharmaceuticals Inc.

Granules Pharmaceuticals Inc. received FDA approval on January 29 for its New Drug Application for lisdexexamfetamine dimethylate to market the generic version of the ADHD medication, a move that is expected to significantly alleviate pended shortages and bolster competition within the stimulant market. The approval positions Granules to capitalize on the high demand for the oral product, potentially reshaping market dynamics amid ongoing staffing constraints at other manufacturers.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed